Teclistamab for new advanced AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your amyloidosis must be confirmed by a biopsy.
- You must have stage IIIB (advanced) AL amyloidosis based on the Mayo 2004 staging system.
- A specific blood test (dFLC) must be at least 50 mg/L.
- You cannot have an uncontrolled infection or another active cancer.
- You cannot have multiple myeloma or Waldenstrom macroglobulinemia (related blood cancers).
- Your heart and other organs must meet basic health requirements (e.g., no severe heart block or dangerously low blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.